Zhitong Finance App News, Fuyuan Pharmaceutical (601089.SH) issued an announcement. Recently, the company received a rotigotin patch (specification: 2 mg/24 hours, 4.5 mg/patch) and “Drug Registration Certificate” (certificate number: 2026S03864) from the State Drug Administration to approve the production of the drug.

Rotigotin patches developed by Ushibi first passed the EU centralized review and marketing in February 2006. In June 2018, after approval by the State Drug Administration, rotigotin patches were marketed domestically. The drug is used as a single agent for early idiopathic Parkinson's symptoms and signs (not in combination with levodopa), or in combination with levodopa at all stages of the disease until the efficacy of levodopa decreases, is unstable, or fluctuates in advanced stages of the disease (end-of-dose phenomenon or “switch” phenomenon).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.